DisclosureWe earn commission on partner links; ranking is set by our evidence-based methodology — not advertisers. Read policy
Ozempic is semaglutide approved for type 2 diabetes. Often prescribed off-label for weight loss.
A proven diabetes drug, not a weight-loss shortcut
For adults with type 2 diabetes, Ozempic is one of the most well-supported options available: it reliably lowers blood sugar, has shown cardiovascular and kidney benefits in high-risk patients, and produces modest weight loss as a secondary effect. But it is FDA-approved for diabetes (plus cardiovascular and kidney risk reduction in qualifying patients), not for obesity, so using it solely for weight loss is off-label, and people in that situation should ask their doctor about Wegovy, which contains the same molecule at a higher dose and is approved for weight management. Expect real, usually manageable GI side effects and a high list price.
We may earn a commission if you buy through this link, at no extra cost to you. It never affects our score. How we make money
Ozempic is the brand name for semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist made by Novo Nordisk and delivered as a once-weekly subcutaneous injection from a prefilled pen. The FDA first approved it in December 2017.
Its approved indications are narrower than its reputation suggests. Per the FDA label, Ozempic is indicated, as an adjunct to diet and exercise, to:
Critically, Ozempic is not FDA-approved for weight loss or for obesity (FDA). It is not approved for use in type 1 diabetes. The same molecule, semaglutide, is sold as Wegovy at higher doses (up to 2.4 mg) with an explicit weight-management indication, and as Rybelsus in an oral tablet form for type 2 diabetes. The widespread use of Ozempic specifically for weight loss is off-label prescribing — common, often effective, but outside the FDA-reviewed indication.
Semaglutide mimics GLP-1, a natural incretin hormone the gut releases after eating. By activating GLP-1 receptors, it works through several complementary mechanisms (NIH/StatPearls):
The "semaglutide" molecule is engineered for a long half-life (around one week), which is what makes once-weekly dosing possible — a meaningful convenience advantage over older daily GLP-1s such as liraglutide.
Ozempic's evidence base — the global SUSTAIN phase 3 program plus dedicated outcomes trials — is one of the most mature in the GLP-1 class.
Across the SUSTAIN trials, semaglutide produced A1c reductions of roughly 1.0% to 1.8%, varying by dose and the comparator. In Novo Nordisk's labeling, the majority of patients on the 1 mg dose reached the American Diabetes Association target of A1c below 7%. The higher 2 mg dose, approved in 2022, delivered modestly greater A1c reduction than 1 mg (FDA; PRNewswire 2022). In head-to-head trials, semaglutide generally outperformed other injectable GLP-1s such as dulaglutide on glucose lowering.
Although not a weight-loss drug on label, Ozempic consistently produced clinically meaningful weight reduction as a secondary outcome in SUSTAIN — typically on the order of several kilograms, more than older diabetes drugs. This is less than the weight loss seen with Wegovy (semaglutide 2.4 mg), which is dosed and studied specifically for that purpose. If weight loss is the primary goal, the on-label, higher-dose product exists for a reason.
This is where Ozempic moved from "good glucose drug" to standard-of-care. In SUSTAIN-6, a double-blind trial of 3,297 patients with type 2 diabetes at high cardiovascular risk, semaglutide reduced the composite of cardiovascular death, nonfatal heart attack, and nonfatal stroke by 26% versus placebo (hazard ratio 0.74) over a median 2.1 years (Marso SP et al., NEJM 2016;375:1834-1844; PMID 27633186). That result underpins the FDA cardiovascular-risk-reduction indication.
In the FLOW trial (3,533 adults with type 2 diabetes and chronic kidney disease), once-weekly semaglutide 1 mg reduced the risk of major kidney outcomes — a composite including kidney failure, a 50% drop in eGFR, and kidney/cardiovascular death — by 24% versus placebo (NEJM 2024; NCT03819153). FLOW also showed lower risk of cardiovascular events and all-cause death. The trial was stopped early for efficacy and led to the 2025 kidney indication.
Honest caveat: these are relative risk reductions in defined high-risk populations. Absolute benefits are smaller, and individual results — especially for weight — vary widely. The trials enrolled people with diabetes; the cardiovascular and kidney findings should not be assumed to transfer wholesale to people without diabetes taking the drug off-label.
Ozempic is titrated slowly to limit gastrointestinal side effects (FDA label):
It is injected subcutaneously in the abdomen, thigh, or upper arm, on the same day each week, with or without food. Doses can be given at any time of day. If a dose is missed, it can be taken within 5 days; otherwise it is skipped. Rushing the titration is the most common avoidable cause of intolerable nausea.
Ozempic carries an FDA boxed warning for thyroid C-cell tumors: semaglutide caused dose- and duration-dependent thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in rodents. Whether this risk applies to humans is unknown (FDA). It is contraindicated in anyone with a personal or family history of MTC, or with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
The most common adverse reactions are gastrointestinal — nausea, vomiting, diarrhea, abdominal pain, and constipation. Nausea is the most frequent, affecting roughly one in five patients in trials, and GI symptoms are the leading reason people discontinue (FDA; NIH). These are usually dose-related and tend to ease over weeks as the body adapts, which is the rationale for slow titration.
The label flags several less common but important risks (FDA):
Semaglutide is not recommended during pregnancy, and the manufacturer advises discontinuing it at least 2 months before a planned pregnancy because of the long half-life.
Because Ozempic slows gastric emptying, it can affect the absorption of oral medications taken at the same time; clinically the most-watched interactions are with insulin and sulfonylureas (hypoglycemia risk). Anyone on multiple medications should review the regimen with a prescriber or pharmacist.
Best for: adults with type 2 diabetes, particularly those who also have established cardiovascular disease or chronic kidney disease, where Ozempic offers organ-protective benefits beyond glucose control. It is a strong fit for people who value once-weekly dosing and want a single drug that addresses sugar, weight, heart, and kidney risk together.
Should skip or use caution: anyone with a personal or family history of medullary thyroid cancer or MEN 2 (absolute contraindication); people with a history of pancreatitis; those with type 1 diabetes (not indicated); and anyone who is pregnant or planning pregnancy. People whose *only* goal is weight loss and who do not have diabetes are arguably better served by the on-label product, Wegovy, both clinically and for insurance coverage.
Ozempic is expensive. The U.S. list price is roughly $1,000 per month before any discounts, and it is the same regardless of which dose strength you use (GoodRx; manufacturer). Few people pay full list price:
Verify current pricing directly, as manufacturer programs and list prices change frequently. The practical takeaway: cost and insurance coverage often determine real-world access more than clinical suitability does.
For adults with type 2 diabetes, Ozempic is a genuinely top-tier, evidence-rich medication: meaningful A1c reduction, proven cardiovascular benefit (SUSTAIN-6), proven kidney protection (FLOW), and the convenience of once-weekly dosing. Its main downsides are cost, frequent (usually transient) GI side effects, the thyroid-tumor boxed warning, and contraindications that must be screened for.
The most important honesty check is the indication itself. Ozempic is a diabetes drug. If you have diabetes — especially with heart or kidney disease — it is one of the best-supported choices available. If you are healthy and simply want to lose weight, the on-label, higher-dose alternative (Wegovy) or tirzepatide (Zepbound) is the more appropriate, better-covered, and better-studied path. Either way, this is a prescription medication with real risks: the decision belongs with a qualified prescriber who knows your full history, not with a marketing claim.
*This article is independent editorial analysis for general information and is not medical advice. HealthVetted accepts no payment for placement and sells none of the products it reviews. Consult a licensed clinician before starting, stopping, or changing any medication.*
Ozempic's active ingredient, semaglutide, is a GLP-1 receptor agonist: it mimics glucagon-like peptide-1, a natural gut hormone released after eating. It prompts the pancreas to release more insulin when blood sugar is high, suppresses glucagon (a hormone that raises blood sugar), and slows stomach emptying. It also acts on appetite centers in the brain to reduce hunger and food intake, which is why many people eat less and lose some weight.
Active ingredient: Semaglutide
Across the SUSTAIN clinical trial program, Ozempic lowered A1C by roughly 1.0 to 1.8 percentage points depending on dose and starting level, with average weight reductions of about 6 to 14 lb (roughly 2.5 to 6.5 kg) at the 0.5 mg and 1 mg doses, and more at 2 mg. In the SUSTAIN-6 cardiovascular outcomes trial (3,297 patients with type 2 diabetes at high cardiovascular risk, published in NEJM in 2016), semaglutide reduced the primary composite of cardiovascular death, nonfatal heart attack, or nonfatal stroke by 26% versus placebo (6.6% vs 8.9%; hazard ratio 0.74, 95% CI 0.58 to 0.95). That composite benefit was driven mainly by a significant drop in nonfatal stroke; reductions in nonfatal heart attack and cardiovascular death individually were not statistically significant, and the trial notably found a higher rate of diabetic retinopathy complications in the semaglutide group. SUSTAIN-6 was designed as a safety (non-inferiority) trial that went on to show superiority on the composite. The separate 2024 FLOW trial showed a 24% reduction in a combined kidney-and-cardiovascular outcome, supporting the 2025 chronic kidney disease indication.
A realistic timeline of what Ozempic users typically experience. Individual results vary; this is educational, not medical advice.
You begin at 0.25 mg once weekly. This is a tolerability dose, not a treatment dose, meant to let your body adjust. Nausea, and sometimes diarrhea or constipation, often appear in the first 1-2 days after an injection and tend to be worst this month. Blood-sugar or weight changes are usually minimal so far.
Your prescriber typically raises the dose to 0.5 mg weekly. Semaglutide reaches steady levels in the blood around 4-5 weeks, so this is when most people start noticing reduced appetite and early blood-sugar improvement. A brief return of nausea is common after each dose increase, then usually settles.
If more blood-sugar control is needed, the dose may step up to 1 mg (and later to a 2 mg maximum), each increase spaced about 4 weeks apart. For most people GI side effects have faded by roughly weeks 6-8. Appetite suppression and gradual weight change are often more noticeable, though responses vary widely.
This is when pivotal trials measured the main effect: in SUSTAIN 1, about 73% of people on 0.5 mg reached an A1C of 7% or under by 30 weeks. Expect your clinician to recheck A1C and weight around this point. Note: Ozempic is FDA-approved for type 2 diabetes; any weight loss is a secondary effect and not guaranteed.
Once you reach an effective dose, you stay on a once-weekly injection long term. Benefits to blood sugar and weight generally persist only while you keep taking it; trials show effects can diminish after stopping. Ongoing follow-up monitors A1C, side effects, and dose adjustments. Individual results vary.
The most common side effects (reported in at least 5% of patients) are gastrointestinal: nausea (about 16-20%), vomiting, diarrhea, abdominal pain, and constipation. These are usually worst early on or after a dose increase and often ease over time; eating smaller, lower-fat meals can help. Serious but less common risks include pancreatitis (severe, persistent abdominal pain), gallbladder problems, acute kidney injury from dehydration, low blood sugar (especially when combined with insulin or sulfonylureas), worsening diabetic retinopathy, and allergic reactions. Ozempic carries an FDA boxed warning because semaglutide caused thyroid C-cell tumors in rodents; whether it does so in humans is unknown, but it is contraindicated in people with a personal or family history of medullary thyroid cancer or MEN 2. Tell your doctor about any persistent abdominal pain, vision changes, or signs of an allergic reaction.
Sourced from FDA labeling and clinical references; not exhaustive and not a substitute for your prescriber or pharmacist. Always disclose every medication and supplement you take.
Starts at $997/mo from Novo Nordisk.
As of 2026, Ozempic's list price (WAC) is roughly $935 per month, and retail cash prices at major pharmacies run about $935-$969 per month without insurance or discounts. Novo Nordisk's NovoCare direct self-pay program offers cash prices of about $349/month for the 0.25, 0.5, and 1 mg pens and about $499/month for the 2 mg pen, with an introductory offer near $199/month for some new patients on the 0.25 mg and 0.5 mg doses through June 30, 2026. Commercially insured patients with coverage may pay as little as $25/month using the manufacturer savings card, but that lowest pricing is capped (up to $100/month in savings, for a limited number of months) and excludes people with government insurance. Medicare and Medicaid typically cover Ozempic for diabetes (but not for off-label weight loss), and a Patient Assistance Program provides free medication to qualifying low-income, uninsured patients. GoodRx-style coupons usually trim the retail price only modestly. Confirm current pricing and your own coverage before starting.
Prices current as of May 29, 2026 and exclude promo codes; cash-pay and channel pricing change frequently — confirm with the pharmacy or provider.
If you have type 2 diabetes, especially with heart or kidney disease, Ozempic is a strong, evidence-backed choice with cardiovascular and renal benefits few diabetes drugs can match. If your only goal is weight loss, Wegovy is the on-label sibling. Either way, plan for GI side effects, weekly injections, and a frank conversation about cost and insurance. Only a licensed clinician can decide whether Ozempic is right for you; this is general information, not medical advice.
No. Ozempic is FDA-approved for type 2 diabetes, for reducing cardiovascular risk in those with heart disease, and for slowing chronic kidney disease in diabetes, not for weight loss. Its sister drug Wegovy contains the same medication (semaglutide) at a higher dose and is FDA-approved for chronic weight management.
In type 2 diabetes trials, people lost roughly 6 to 14 lb on average over about 30 to 56 weeks, depending on the dose. Weight loss is a secondary effect of Ozempic, not its primary purpose, and tends to be greater with the higher-dose, weight-loss-specific drug Wegovy. Individual results vary.
Both contain the same active drug, semaglutide. Ozempic is FDA-approved for type 2 diabetes (plus cardiovascular and kidney risk reduction) and tops out at 2 mg weekly; Wegovy is FDA-approved for weight management and is dosed higher (up to 2.4 mg weekly), generally producing more weight loss.
Blood-sugar effects begin within the first few weeks, but it typically takes about 4 to 8 weeks at an effective dose (0.5 mg or higher) to see a meaningful A1C improvement. Weight changes usually appear gradually over several months.
The most common side effects are gastrointestinal: nausea (about 16-20% of patients), vomiting, diarrhea, abdominal pain, and constipation. They are usually worst when starting Ozempic or increasing the dose and often improve over time. Tell your doctor about severe or persistent symptoms.
Avoid Ozempic if you or a family member has had medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), or if you have had a serious allergic reaction to semaglutide. It is also not for type 1 diabetes. Use caution with a history of pancreatitis, gallbladder disease, or diabetic retinopathy, and discuss pregnancy with your doctor.
As of 2026, the list price is about $935 per month, and retail cash prices run roughly $935 to $969 per month. Novo Nordisk's NovoCare self-pay program offers lower cash prices (about $349/month for most pens, $499/month for the 2 mg pen), and commercially insured patients may pay as little as $25/month with the savings card, though that lowest price is capped and time-limited.
Blood sugar usually rises again and much of any weight lost tends to return, because the drug's appetite and metabolic effects are active only while you take it. Do not stop Ozempic on your own; discuss any changes with your doctor first.
For most people, Ozempic is a long-term therapy. Type 2 diabetes is a chronic condition, and the blood-sugar, weight, and cardiovascular benefits generally persist only while treatment continues. Your doctor can advise on how long you should stay on it.
Affiliate link — we may earn a commission at no extra cost to you, and it never changes our rankings or score. Disclosure
Legitimate ways to lower your cost. We don’t sell Ozempic — this is independent guidance, not medical or financial advice. Confirm current terms with the program and your clinician.
The maker of Ozempic runs a commercial-insurance savings program that can lower your copay. See the official Ozempic savings page → Eligibility rules apply and these programs typically exclude government insurance (Medicare/Medicaid).
If you’re uninsured or low-income, free or reduced-cost medication may be available through patient assistance programs. Search MedicineAssistanceTool (PhRMA) and NeedyMeds.
Filling a 90-day supply instead of monthly often lowers the per-month cost and cuts pharmacy trips. Ask your prescriber and pharmacy whether it’s an option for you.
A different formulation or product may cost less for a similar result. Compounded GLP-1 · Supplements vs GLP-1.
Same-category options, scored on the same six-axis rubric. Higher is better.